Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 1 Interventional

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

ClinicalTrials.gov ID: NCT02546661

Public ClinicalTrials.gov record NCT02546661. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 8:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment (BISCAY).

Study identification

NCT ID
NCT02546661
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
AstraZeneca
Industry
Enrollment
117 participants

Conditions and interventions

Interventions

  • AZD4547 Drug
  • MEDI4736 Drug
  • Olaparib Drug
  • AZD1775 Drug
  • Vistusertib Drug
  • AZD9150 Drug
  • Selumetinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 130 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 27, 2016
Primary completion
Mar 17, 2020
Completion
Jan 29, 2026
Last update posted
Dec 28, 2025

2016 – 2026

United States locations

U.S. sites
8
U.S. states
6
U.S. cities
6
Facility City State ZIP Site status
Research Site Los Angeles California 90095
Research Site New Haven Connecticut 06510
Research Site Fort Myers Florida 33901
Research Site New York New York 10029
Research Site New York New York 10032
Research Site New York New York 10116
Research Site Cleveland Ohio 44195
Research Site Nashville Tennessee 37203

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02546661, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 28, 2025 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02546661 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →